Filing Flows › Bioadaptives (BDPT) › Q2 2026 › vs Q2 2025
Bioadaptives (BDPT) Q2 2026 vs Q2 2025 (year over year)
Bioadaptives's revenue rose $2K (+55%) from $3K in Q2 2025 to $5K in Q2 2026.
Bioadaptives, Q2 2026: revenue $5K (+55% year over year), net earnings $150K, operating cash flow −$44K. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $5K | $3K | $2K | +55% |
| Other income, net | $347K | $121K | $226K | +186% |
| Costs & expenses | $352K | $282K | $70K | +25% |
| Operating costs | $202K | $282K | −$80K | -28% |
| Net earnings | $150K | −$158K | $308K | — |
| Cost of revenue | $1K | $2K | −$1K | -65% |
| General & admin | $178K | $198K | −$20K | -10% |
| Other operating costs | $24K | $82K | −$59K | -71% |
| Operating cash sources | $196K | −$47K | $243K | — |
| Depreciation | $2K | $0 | $2K | — |
| Cash used in operations | $44K | $111K | −$67K | -60% |
| Working capital & other | $196K | −$18K | $214K | — |
Questions
How much did Bioadaptives's revenue grow year over year in Q2 2026?
Bioadaptives's revenue rose $2K (+55%) from $3K in Q2 2025 to $5K in Q2 2026.